ANCA Vasculitis News

July 9, 2020July 9, 2020

Blood suPAR Levels May Help Assess Disease Severity, Prognosis in AAV Patients

Blood levels of the soluble urokinase plasminogen activator receptor (suPAR) protein may be a helpful tool for assessing disease severity and prognosis in people with ANCA-associated vasculitis (AAV), a new ... Read more

July 2, 2020July 6, 2020

AAV Rare in COPD Patients With AAT Deficiency

ANCA Vasculitis News

Low levels of the protein alpha-1-antitrypsin (AAT) do not appear to be enough to increase the risk of ANCA-associated vasculitis (AAV) in people with chronic obstructive pulmonary disease (COPD) — ... Read more

June 29, 2020June 29, 2020

Eligibility, Outcome Measures Need Uniformity Across AAV Clinical Trials, Review Says

ANCA Vasculitis News

Clinical trials testing new treatments for people with ANCA-associated vasculitis (AAV) need more uniformity in the patients they recruit and in the outcome measures used for efficacy assessments, a new ... Read more

June 25, 2020June 25, 2020

Monash Researcher Awarded Grant to Study Tolerogenic Dendritic Cells

ANCA Vasculitis News

The Vasculitis Foundation awarded its “Dr. Chris Cox-Marinelli Young Investigator Award” — a one-year research grant totaling $49,822 — to Dragana Odobasic, PhD, a research fellow at Monash University in ... Read more

June 22, 2020June 22, 2020

Depression More Common in AAV, Linked to Pain, Lower Quality of Life

ANCA Vasculitis News

Depression is more common in people with primary systemic vasculitides, including in those with ANCA-associated vasculitis (AAV), than in healthy people, a review study has found. Depression in vasculitis patients was ... Read more

June 17, 2020June 17, 2020

Cigarette Smoking Linked to Greater Likelihood of MPO-positive AAV

ANCA Vasculitis News

Cigarette smoking significantly increases the odds of developing ANCA-associated vasculitis (AAV), particularly the disease form with antibodies against the myeloperoxidade (MPO) protein, and this risk is stronger in people with ... Read more

June 15, 2020June 15, 2020

Kidney Involvement at AAV Diagnosis Predicts Major Renal Relapses, Study Finds

ANCA Vasculitis News

People with ANCA-associated vasculitis (AAV) who have kidney involvement when they are diagnosed are more likely to experience major kidney relapses later, a new study shows. The study also indicates ... Read more

June 11, 2020June 11, 2020

Guidelines Given for Rituximab as Maintenance Therapy in 3 AAV Subtypes

ANCA Vasculitis News

Guidelines for using rituximab as a maintenance therapy in adults with ANCA-associated vasculitis (AAV) were recently published that, in addition to helping physicians with treatment approaches, highlight areas where more ... Read more

June 9, 2020July 11, 2020

Coalition Will Address Racial Disparities in Rare Disease Communities

ANCA Vasculitis News, COVID-19 News

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for ... Read more

June 8, 2020June 8, 2020

Trial Supports Long-term Maintenance Therapy With Rituximab

ANCA Vasculitis News

Continuing maintenance treatment with rituximab for long periods increases the likelihood that people with ANCA-associated vasculitis (AAV) remain in remission, without increasing the incidence or severity of adverse events, findings ... Read more

June 4, 2020June 4, 2020

Mycophenolate Mofetil May Be Alternative to Cyclophosphamide, Analysis Shows

ANCA Vasculitis News

Mycophenolate mofetil (MMF) may be a safe and effective alternative to the standard induction therapy cyclophosphamide in certain ANCA-associated vasculitis (AAV) patients, a review study reports. Based on the data, researchers ... Read more

June 1, 2020June 1, 2020

First Part of IFX-1 Trial in AAV Patients in EU Fully Enrolled, InflaRx Says

ANCA Vasculitis News, COVID-19 News

InflaRx announced it has fully enrolled the first part of its Phase 2 trial assessing the safety and efficacy of IFX-1 in people with ANCA-associated vasculitis (AAV) in Europe. The ... Read more

May 20, 2020June 20, 2020

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

ANCA Vasculitis News, COVID-19 News

Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic. The ... Read more

May 18, 2020May 18, 2020

Request for FDA Approval of Avacopan Likely by Mid-year, ChemoCentryx Says

ANCA Vasculitis News, COVID-19 News

ChemoCentryx is planning to file a request with the U.S. Food and Drug Administration (FDA) by mid-year seeking approval of avacopan (CCX168) as a treatment for people with ANCA-associated vasculitis (AAV), the company said. ... Read more

May 12, 2020June 13, 2020

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

ANCA Vasculitis News, COVID-19 News

The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey ... Read more